Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 03, 2004. The report details a share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 17, 2004, and an application for block listings of new shares for employee option plans.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure activities:
- Share Repurchase: 500,000 ordinary shares purchased on November 02, 2004.
- Repurchase Price: 1,167.62 pence per share.
- Treasury Holdings: Post-transaction total of 49,478,000 shares held in Treasury.
- Shares in Issue: 5,886,425,106 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the repurchase of 500,000 shares, which are now held in Treasury. Additionally, the Company has applied to the UK Listing Authority and the London Stock Exchange for block listings totaling 2,500,000 ordinary shares to be issued under various executive and savings-related share option plans.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 500,000 share repurchase (500,000 shares x 1,167.62 pence).
- Confirm the impact of the 2,500,000 new block listings on future dilution once issued.
- Check the specific breakdown of the 2,500,000 block listings across the five different share option plans mentioned.
- Review the Company's 20-F annual report for comprehensive financial performance data not included in this 6-K.